MR MRK Merck & Co., Inc. 로딩 중... : 애널리스트의 강세 및 약세 의견

Pfizer references Merck's pembrolizumab as a benchmark for combination opportunity, emphasizing the clinical utility of the regimen.

Pfizer will advance directly to a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes, aiming to maintain leadership in the adult market. — This next-gen vaccine targets broader serotype coverage, strengthening Pfizer's competitive position against Merck's adult pneumococcal vaccine.

Pfizer's pipeline prioritization has led to a ~$4.4B non-cash impairment, including deprioritizing disitamab vedotin in bladder cancer due to competition from its own PADSEV, indicating a strategic resource shift within oncology. — Shows a direct market access trade-off between Roche's Padcev and its own pipeline, potentially reducing future competitive pressure from a different mechanism of action.